||We have tried to position Guilford so that our partnering stems from strategic opportunity, not financial need. We seek partners who share our commitment to speed, quality and results and our mission to make a difference by making new medicines. We seek partners who share our values of clear thinking, resourcefulness, adaptability, nimbleness, perseverance, feel for clinical practice and patient needs, constant communication, consistent commitment and the will to make our own luck.
SVP Corporate Development, General Counsel and Secretary
Daiichi Radioisotope Laboratories (DRL)
Orion Pharma - for the Scandinavian marketing of GLIADEL®
Wafer (polifeprosan 20 with carmustine implant). Orion received exclusive marketing, sales, and distribution rights
to GLIADEL® Wafer in Finland, Sweden, Norway, and Denmark.
Guilford manufactures and supplies GLIADEL® Wafer to Orion.
Guilford received an up-front payment, and receives transfer payments
on product sales to Orion.
Orion Pharma web site
Daiichi Radioisotope Laboratories (DRL) - for the development and
marketing of DOPASCAN® Injection in parts of Asia. DRL
received exclusive marketing, sales, and distribution rights to DOPASCAN®
Injection in Japan, Korea, and Taiwan. Guilford is responsible for manufacturing
and supplying the DOPASCAN® Injection precursor to DRL.
DRL will radiolabel the precursor to make the final DOPASCAN®
Injection product. Guilford received an up-front payment, and will receive
milestone payments and royalties on product sales.
Radioisotope Laboratories (DRL) web site
MAP Medical Technologies - for the development, marketing, sales
and distribution rights to DOPASCAN® Injection for all
European Union Member States and other select markets. MAP is responsible
for seeking regulatory approvals, and for manufacturing, marketing and
selling DOPASCAN® Injection in these countries. Guilford
received an upfront payment and will receive milestone payments, and royalties
on future product sales of DOPASCAN® Injection within MAP's
MAP Medical Technologies